Introduction
Skeletal muscle injuries and diseases constitute a common form of ailment in the human body. The normal repair process of muscle injury involves the activation of a quiescent population of resident muscle progenitor stem cells known as satellite cells (SCs). The formation of new muscle fibres, or myogenesis, begins with activation of these SCs, followed by a proliferation phase, a differentiation phase into myocytes, the formation of myofibre by cell fusion and, finally, integration into the existing skeletal muscle [1] . Despite an inherent capability of skeletal muscle for regeneration, there are certain conditions that prevent the repair process from culminating in healthy muscle tissue, instead leading to atrophy, morbidity and loss of function. For example, massive loss of muscle tissue associated with traumatic injuries can hinder the repair process and prevent long-term functional recovery. In addition, certain muscle wasting diseases can prevent normal muscle tissue regeneration pathways. Some recent advances in therapy aimed at enhancing muscle repair involve skeletal muscle cell therapy, or the augmentation of resident stem cell populations with autologous or allogeneic stem cells [2] . This form of cell therapy has become a leading area of research and a means of overcoming some of the most challenging obstacles in the regeneration of skeletal muscle biomaterial-based delivery for skeletal muscle repair [3] [4] [5] [6] , even for the most complicated disease states such as muscular dystrophy (MD).
MDs comprise a heterogeneous group of genetic disorders, whereby various genes controlling muscle function are either mutated or defective. MDs primarily manifest as progressive muscle wasting and weakness of variable distribution and severity [7, 8] . Among the diverse phenotypes of MD that have been recognized, there are nine thoroughly investigated types subdivided & 2018 The Author(s) Published by the Royal Society. All rights reserved.
according to the distribution of predominant muscle weakness. For example, Duchenne muscular dystrophy (DMD) is the most prevalent form in children, with an incidence of 200 per million births, or roughly 1 in every 5000 boys [9] . Recent newborn screening indicates that the incidence of DMD may be closer to 1 : 6000 boys [10] . A majority of DMD cases are genetically inherited; however, approximately 35% of DMD cases are de novo mutations that arise during pregnancy, irrespective of family history [11] . Myotonic dystrophy and facioscapulohumeral MD (FSHD) are the most common forms observed in adults, each form affecting more than 1 in 8000 people worldwide [12] . Becker's muscular dystrophy (BMD) is accompanied by a partial loss of functional dystrophin and displays milder symptoms when compared with DMD [13] [14] [15] . As the disease progresses, DMD patients eventually lose ambulatory function and require a wheelchair; respiratory insufficiency occurs after the loss of ambulation as a result of the generalized weakness of the inspiratory and expiratory muscles. Ultimately, DMD shortens the lifespan of the patient due to cardiac complications and respiratory challenges [13] . The underlying mechanism by which DMD leads to muscle wasting is based on repetitive degeneration and regeneration cycles that occur in dystrophic muscles, leading to the exhaustion of the SC pool and the replacement of the muscle fibres by fibrotic and adipose tissues [16, 17] . Different phenotypes of MD exert different influences on skeletal muscles. Therefore, treatment strategies are often tailored to the specific type of the disease, taking into account the extent of muscle damage and their condition. Regrettably, despite significant progress made towards understanding the underlying molecular mechanisms of the disease, there are no clinically approved treatments available for reversing the course of any of the MDs. Instead, medications and supportive therapy, such as physiotherapy, steroid medication and orthopaedic surgery, can help to manage symptoms and slow the course of the disease. Several experimental therapeutic approaches are currently under investigation, including gene therapy, pharmacological therapy and cell therapy, all of which concentrate on promoting muscle repair and regeneration or partial rehabilitation [8, 18] .
Cell transplantation may play an important role in the development of new regeneration strategies for muscle injures in general, and specifically for reversing the muscle damage associated with MDs. A wide variety of cell types, including SCs and myoblasts, have been investigated for this purpose. In principle, augmenting the populating of SCs with autologous or allogeneic muscle progenitor cells (MPCs) can enhance the de novo formation of myofibril in skeletal muscle injuries and dystrophic muscles [1] . However, cell therapy may not be suitable for all forms of muscle injury, let alone DMD, where the harsh environment associated with the dystrophic muscles-in addition to the wide extent of the damage-compounds the challenges of this task (beyond correcting the mutated dystrophin genes). The extent of the injury or disease, the age of the patient and the muscle pathophysiology are a few of the main factors that must be considered when evaluating the feasibility of a cell therapy approach. For example, even in the case of muscle loss due to trauma-where muscle is not necessarily diseased-it may be very difficult to treat a large injury with grafts of a limited number of MPCs. Likewise, the intra-muscular delivery to whole body muscles is unrealistic for treating those forms of MD that affect the majority of the patient's muscles, such as DMD, because this would require hundreds or thousands of intra-muscular injections. Localized forms of MD, however, such as oculopharyngeal MD (OPMD), FSHD and distal MD (DD), which are limited to few, specific and relatively small muscles, could be treated by local injections. Under such circumstances, it may be possible to successfully apply a cell therapy approach for reversing the course of MD.
Even beyond the issues of graft size and cell delivery options, host inflammation remains a major putative factor associated with poor outcome in cell therapy. In post-traumatic injuries, cell therapy may be more likely to succeed if the implantation occurs during a specific phase of the host inflammatory response to the injury. For MD, this can be more challenging because the dystrophic muscles tend to be in repetitive cycles of degeneration and regeneration, severely complicating the timing of a successful introduction of a healthy MPC population. Despite this apparent impediment, there are some examples of cell therapy having favourable effects on the muscle regeneration in animal models of MD. For example, preliminary experiments conducted on rodent and dog models for DMD as well as other MDs, demonstrated partial restoration of the damaged myofibres following the transplantation of MPCs [19] [20] [21] . Although representing a significant step towards the discovery of treatments for MDs, these attempts at promoting skeletal muscle regeneration in pre-clinical models are still very much hindered by poor cell survival and sub-optimal integration of grafted cells with the existing skeletal muscle.
Early cell therapy clinical trials in MD patients demonstrated the potential contribution of implanted myoblasts in muscle regeneration; however, the issue of poor cell survival was also underscored by these studies. Limited donor cell engraftment, presumably due to immune rejection as well as poor migration of the injected cells, was the putative factor that limited the regeneration of the host musculature [22 -24] . Nevertheless, it is noteworthy that cell transplantation for MDs has reached a stage of advanced clinical trials. A phase I/IIa clinical study (NCT00773227) has been conducted using autologous myoblast transplantation in adult OPMD patients via local intra-muscular injections. A recently completed phase I/II clinical study for DMD patients (EudraCT no. 2011-000176-33) used systemic delivery in which HLA-matched donor-derived mesoangioblasts (MABs) were transplanted intra-arterially. In the OPMD case, where the dystrophic phenotype is limited to pharyngeal muscles, local administration allows for the better efficacy of muscle repair and the results were encouraging. Patients were reported to have two years with an improved quality of life without deterioration of their swallowing function. Although there was massive donor cell death in the hostile environment of the dystrophic muscle, the implantation of large numbers of myoblasts was successfully able to partially (and transiently) repair small muscle groups [25] . These initial results point more to a proof-of-concept for muscle cell therapy in MD, rather than a therapeutic endpoint for treating the injury or disease. Of course, there are still daunting hurdles to overcome in order to reach clinical efficacy for a much larger scale and for treating more prevalent forms of muscle injury or disease. As of now, it seems that the most promising therapeutic application of muscle repair using cell therapy would involve localized repair of the most severely damaged muscles, particularly small muscles, such as those affected by OPMD.
In an attempt to address the limitations in cell survival and post-transplantation retention of the graft, as highlighted by some early clinical trials, experimental studies have largely focused on developing biomaterial-based cell therapies as a means to advance deliverable, viable and sufficient number of cells into injured, diseased or aged skeletal muscle tissues. Protecting the donor cells with an encapsulating biomaterial could make a real difference with this form of cell therapy. For example, the encapsulation of the cells in a protective environment using scaffold technologies can circumvent some of inflammation-related limitations and substantially improve efficacy, while reducing the number of cells required for therapy [3] . Alternatively, skeletal muscle tissue engineering strategies rely on the combination of biomaterial scaffolds, cells, growth factors and in vitro maturation; therefore, representing an ideal approach for treating muscle injuries or MDs. The in vitro tissue engineering strategy attempts to develop artificial contractile muscle constructs by culturing cells on a biomaterial substrate until a functional tissue matures, and this can be employed either as a drug screening device, as a potential whole muscle replacement, or as a partial muscle graft that can readily be transplanted into the patient figure 1. The in vivo strategy relies on cell transportation to the muscle tissues, mainly based on the delivery of living therapeutic cells, with the aim to enhance the regeneration and repair of the damaged skeletal tissue either by integrating into the host muscle tissue or by stimulating the body's own regenerative mechanisms to promote the formation of a new tissue [26] [27] [28] .
Although extensive work has been done during the past few years, tissue engineering technologies have yet to produce a reliable clinical product for treating muscle injuries and MDs. The path from bench to bedside for muscle tissue engineering technologies aimed at curing or alleviating MD is particularly riddled with challenges, and attempts are constantly being made to counter these difficulties. Utilization of hydrogels for skeletal muscle tissue engineering has been emerging as a promising therapeutic possibility. Hydrogels have been employed, for example, as encapsulating cell delivery vehicles that are instructive in promoting either differentiation or maturation of skeletal muscle cells. Hydrogels have been designed to promote muscle cell integration concurrently with protecting the grafted cells from an environment characterized by chronic inflammation exacerbated by the transplantation procedure [29] [30] [31] [32] . Among the types of hydrogels available, biocompatible and bioresorbable hydrogels are more commonly investigated, as they can be easily translated into clinical practice. More specifically, when it comes to muscle repair therapy, some basic principles should be followed when designing the hydrogel carrier, such as mimicking the skeletal muscle milieu, providing bioactive signalling for muscle differentiation, and designing the resorption of the material to coincide with the in vivo integration of new myofibres. In view of their versatility, hydrogels constitute unique biomaterials widely applied in tissue engineering research and in many muscle disease and injury pathologies. Nevertheless, it is not practical to apply the approach of injecting encapsulating hydrogels for every muscle injury of disease. In fact, its use is most probably limited for intramuscular injections in localized forms of muscle injury and MDs. Importantly, encapsulating hydrogels do potentially offer a different level of efficacy in comparison with systemic delivery of cells. Table 1 [52] gelatin methacryloyl (GelMA) hydrogels with carbon nanotubes (CNTs) motife semi-synthetic C2C12 myoblasts CNTs are aligned as bundles within gelatin methacryloyl (GelMA) hydrogels using dielectrophoresis (DEP) tool; anisotropic and electrically conductive hydrogels [53, 54] gelatin methacryloyl (GelMA) hydrogels with palladiumbased metallic glass sub-micrometre wires (PdMGSMWs) [75] chitosan/b-glycerolphosphate/collagen (C/GP/Co) natural mouse SCs injectable thermosensitive C/GP/Co hydrogel, forming a porous cobweb-like network implant (undergoes thermal gelation in situ) [76] gelatin-PEG-tyramine (GPT) semi-synthetic human adipose-derived stem cells (h-ADSCs) and basic fibroblast growth factor (bFGF) injectable matrix consists of a gelatin-based in situ cross-linkable hydrogel conjugated with tyramine, using a PEG chain as a hydrophilic linker [77] partially oxidized alginate modified with RGD peptides natural IGF-1 and primary mouse myoblasts a degradable, shape-memory and compressible macroporous alginate scaffold (oxidized alginate modified with RGD peptides is covalently cross-linked using carbodiimide chemistry) [78] partially oxidized alginate modified with RGD peptides natural IGF-1, VEGF, and primary mouse myoblasts a degradable, shape-memory and compressible macroporous alginate scaffold (oxidized alginate modified with RGD peptides is covalently cross-linked using carbodiimide chemistry) [79] rsif.royalsocietypublishing.org J. R. Soc. Interface 15: 20170380 objective of this review is to highlight the most prevalently used hydrogels in the field of bioengineering approaches for muscle regeneration following traumatic injury or in the case of MD treatment.
Hydrogels in cell-based therapies
A variety of biomaterials with different physical and chemical properties have been developed to enhance the efficacy of tissue engineering strategies for repairing skeletal muscle defects and dystrophic muscles. Among the host of biomaterials available, hydrogels-three-dimensional (3D) polymeric networks-are particularly attractive biomaterials, capable of absorbing and retaining a large amount of water, and are pliable enough to mould into any shape, size or form. Moreover, hydrogels can exhibit viscoelastic behaviour, often mimicking that of native tissues [80] . Being inherently tunable, the rate of cross-linking and gelation can be controlled both temporally and spatially by altering environmental conditions such as temperature, UV and pH [80, 81] . In the light of these properties, hydrogels have shown great potential to maximize the therapeutic capacity of skeletal muscle cell grafting. Hydrogels employed in muscle regeneration research are compatible with two main methods-the first is based on injectable hydrogels that either provoke endogenous restoration and regeneration or serve as delivery vehicles to carry therapeutic agents such as cells and/or other bioactive molecules which can be released in a controlled manner. The second approach includes hydrogels that can be used as a prefabricated scaffold, either to guide in vitro formation of muscle tissue or to orchestrate in situ muscle tissue regeneration in vivo figure 2. For example, co-delivery of growth factors along with muscle stem/progenitor cells embedded within engineered hydrogel microspheres has been widely used to augment cell viability, vascularization and myogenesis upon cell implantation. In vitro tissue-engineered muscle constructs are evolving to exhibit appropriate structural and mechanical features which lend themselves to promoting better integration when rapid muscle repair is required. Many of these approaches are still in the investigational stages and will require more development before reaching the clinic. However, other applications that can potentially be applied more readily have been found, including tissue analogues that can be used for predicting the effect of new experimental drugs in models displaying muscular disorders. Furthermore, some studies employing biomaterial-based strategies have shed light upon the integration and function of regenerating muscle associated with the support of accelerated angiogenic and neurogenic responses [68, 73] .
Therapeutic cell sources
The state-of-the-art cell-based therapy for muscle regenerative medicine, particularly for the treatment of MDs, is focused on employing the proper cells, as well as optimizing isolation, characterization and bioprocessing of the cells. Multiple cell types have been tested in animal models of muscle injury and MD, including mesenchymal stem cells (MSCs), SCs and myoblasts. Each of these cell types has shown a certain degree of promise towards alleviating the severity of the injury or disease [82] . Different types of myoprogenitor cells can either directly or indirectly promote muscle regeneration. For example, SCs which are known to have high proliferation rates, self-renewal and differentiation capacity into the myogenic lineage, can be directly engaged in skeletal muscle regeneration by generating nascent myofibres that fuse into the damaged muscle tissue [83, 84] . By contrast, MSCs, which are characterized by the ability to suppress inflammatory responses and exhibit regenerative capacity, can The second strategy, an injectable approach, which is considered to be less invasive, involves either a liquid precursor of the matrix that is injected and then formed in situ, or pre-formed hydrogel particles designed to pass through the needle.
rsif.royalsocietypublishing.org J. R. Soc. Interface 15: 20170380 indirectly contribute to the restoration of damaged muscle functionality by augmenting the activation of resident cells through paracrine signalling [85, 86] . Both MSCs and SCs seem to be very promising candidates among stem cells in cell therapy approaches for skeletal muscle regeneration. SCs are muscle stem cells that typically remain quiescent, adhered to the basal lamina ensheathing each muscle fibre, constituting less than 5% of myonuclei in healthy adult human muscle tissue. Signals emitted by damaged myofibres stimulate the migration of SCs to the defective site. The SCs then undergo proliferation and differentiation to form myotubes that are integrated into the host muscle to regenerate its functionality [87, 88] . Several studies using SCs reported that the injection of them into a dystrophic skeletal muscle of mdx mice not only elevated muscle fibre reconstruction but also elicited the formation of dystrophin-positive fibres, enriched the SC compartment in the muscles and enhanced contractile activity [89, 90] . Although potentially beneficial, the availability of SCs might be limited to the muscle tissue harvest source, whereas MSCs can be obtained from various tissues including bone marrow, adipose tissue and umbilical cord blood tissues. Both autologous and allogeneic stem cells can be easily isolated and potentially differentiated ex vivo into skeletal muscle under proper conditions [91 -93] . However, to date, no high-yield MSC engraftment in animal skeletal muscle has been obtained, and despite their trilineage differentiation capacity, MSCs do not readily differentiate into myogenic cells. According to previous studies which were carried out with MSC transplantation in dystrophic mice, the MSC engraftment does not result in functional benefit, apparently due to limited MSC differentiation into skeletal muscle [94] .
Of note is that other progenitors have also been observed to affiliate with skeletal muscle regeneration, inter alia, by expanding the donor cell population. Femoral artery injection of human skeletal muscle-derived pericytes (MPs) into severe combined immunodeficiency (SCID)-mdx mice led to the formation of host muscle fibres and restoration of dystrophin expression [91] . However, this improved myogenesis was limited to postnatal skeletal muscle with only a minimal effect in adult muscle [95] . MABs, known as vessel-associated progenitor cells, have also been reported to ameliorate dystrophin expression and improve muscle function in both mdx mice [96] and golden retriever MD dog models [97] . MABs are able to cross the vessel wall, unlike SCs and myoblasts that have to be delivered directly into the damaged muscle tissue to be properly engrafted [1, 98] . A phase I/II clinical trial for DMD demonstrated the safety and efficacy of HLAidentical allogeneic MAB delivery to DMD patients (EudraCT no. 2011-000176-33).
Large quantities of muscle progenitors can potentially be derived from embryonic stem (ES) or induced pluripotent stem (iPS) cells. Although there is little evidence to suggest that skeletal muscle precursors can be generated in large quantities from ES/iPS cells, their unlimited supply does make them attractive for cell therapy [99] . Darabi et al. [100] recently demonstrated that large quantities of human ES/ iPS cells can be differentiated to myogenic precursors by conditional expression of PAX7. These cells were successfully engrafted into dystrophic muscle to produce human myofibres that stained positive for dystrophin. The conditional in vitro overexpression of PAX7 in these cells was performed with lentiviral vectors, which can risk random genomic integration. To eliminate this risk, Kim et al. [101] used a non-viral approach to the transient expression of PAX7 in ES/iPS cells using minicircle DNA, in order to produce pluripotent stem cell-derived myogenic progenitors that are similar to those generated by lentivirus. Transient expression of PAX7 did manage to produce myogenic progenitors after multiple transfections, but the in vivo engraftment of these progenitors was not comparable with that of lentivirus controls. Therefore, other improved techniques are still being sought to enable effective non-viral PAX7 transfection of ES/iPS cells in muscle repair therapy.
Transplantation of stem/progenitor cells into the damaged muscle requires, first and foremost, sufficient in vitro expansion of cells. Accordingly, the first challenge is to improve the in vitro expansion of muscle stem cells. Cell expansion is problematic because of the rapid loss of the regenerative and self-renewing properties of the cells in vitro, due to the lack of niche signalling that exists only in vivo [89, 102] . SCs, which were cultured on a tissue culture plate even for a short period, have been shown to possess limited regenerative potential due to the loss of stemness and reduced regenerative capacity [89] . To overcome these problems, research has focused on providing the cells with a niche-like environment using biomaterials. Specially designed biomaterials can mimic the mechanical and biochemical properties of the in vivo stem cell niche in order to better maintain the muscle progenitors. The in vitro niche environments enable robust propagation of SCs while preserving their stemness, which is anticipated to potentiate their therapeutic capacity rather than increasing the number of committed myogenic cells [103, 104] . Consequently, the biomaterials can also provide a comprehensive solution for cell expansion and cell integration.
Of course, this effort to find bioprocessing efficiency is concomitant with implantation requirements of the stem cell therapy, including the ability to control intrinsic stemness or myogenicity during in vivo implantation, evading immunosuppression, structurally and functionally integrating with host tissue, and replenishing the muscle resident stem cell population. Although promising, scaffold-free cell therapies still lack important features that would enable fully successful muscle regeneration in this demanding context. Injected cells succumb to inflammatory response, irritated by the piercing of the injection itself and fail to survive longer than a few hours following injection. Apparently, only a minor fraction of the injected cells affect the muscle repair, and so the efficacy of the procedure is inherently flawed. In the case of stability during and after administration, exploiting biomaterials as artificial niches in vivo may improve the procedure in terms of survival and engraftment. More importantly, this ensures that the cells are provided with the particular microenvironment that enables them to interact with resident cells and exert their therapeutic efficacies in a localized area.
Hydrogel biomaterials
Identifying the optimal therapeutic cell source is not necessarily sufficient to ensure cell therapy's imminent success, particularly in the case of MD treatment. Recognizing the right biomaterial cell carrier may be just as critical to the successful cell therapy of muscle injuries or MDs. This is particularly true given that each type of stem cell or rsif.royalsocietypublishing.org J. R. Soc. Interface 15: 20170380 MPC requires its own unique encapsulating milieu, with individual material properties and spatially controlled bioactive patterns. Over the past several years, numerous studies have been carried out in pursuit of maximizing the potential therapeutic utility of cells and growth factors by developing biomaterial-based strategies that support and guide skeletal muscle repair processes for MD and other muscle pathologies. Hydrogels have stood out among the materials being used, because of their inherent ability to encapsulate cells in situ, support cell survival, facilitate integration and ensure protection upon implantation.
Hydrogels can be classified as natural, synthetic or semisynthetic (also known as hybrid). Naturally derived hydrogels usually provide adhesion sites for cell attachment and strong interactions with cells, while synthetically derived hydrogels are deficient in adhesive sites for cell attachment and have non-specific interactions with cells. Hybrid hydrogels, which contain both biological and synthetic elements, can exhibit proteolytic degradability via their biological domains together with exact mechanical properties governed by the synthetic composition [105, 106] . Naturally and synthetically derived hydrogels can be fabricated with a vast range of mechanical and chemical properties that modulate and control over cell behaviour. For example, alginate is a naturally occurring linear polysaccharide typically derived from brown seaweed that has been widely used as a hydrogel for tissue engineering and cell encapsulation applications due to its favourable properties including low toxicity, high biocompatibility and ease of gelation [107] . Possessing a porous microstructure allowing the diffusion of oxygen, nutrients and growth factors makes this material highly suitable as a scaffold for the growth and differentiation of myogenic cells in mass culture and for myoblast engraftment in skeletal muscle regeneration [33, 74] . Among the natural hydrogels, those derived from decellularized extracellular matrix (ECM) have gained much attention due to their ability to conform to irregular shapes and the inherent bioactivity of the matrix source. Controlling the hydrogel properties by using various tissue sources revealed a potential to augment host remodelling response, particularly in a rodent skeletal muscle defect model [34, 105, 108] . An in vitro experiment found that porcine dermal ECM hydrogels supported greater myoblast fusion compared with urinary bladder ECM (UBM) hydrogels. Unlike these in vitro result, UBM hydrogels in vivo degraded more quickly and induced a greater amount of myogenesis than dermal ECM, apparently due to a high content of glycosaminoglycans in the UBM. Consequently, both ECM hydrogels were rapidly infiltrated by host cells and showed signs of myogenesis after 35 days of hydrogel implantation [34] . This outcome further underscores the complicated interactions that occur between the host cells, the donor cells, the material and the in vivo microenvironment.
Another widely used natural biological material is fibrin, which is a major component of blood clots that is found mainly in skeletal muscle tissues undergoing repair. At a wound site, the fibrin is generated from its precursor, fibrinogen, by the enzymatic action of thrombin. Fibrin has many inherent properties that confer an advantage for tissue repair in hydrogels used for skeletal muscle tissue regeneration strategies. This material has also been shown to increase the therapeutic efficacy of treatments for skeletal muscle disorders [29, 32] . It has been reported already over a decade ago that exploiting fibrin gels for the delivery of primary myoblasts into rat gracilis skeletal muscle facilitates the integration of donor cells into host muscle fibres in a localized and time-dependent manner [69] . More recently, the delivery of human muscle cell to injured muscles of immunocompromised mice, seeded within fibrin gel that was manipulated in vitro to form microthreads, was shown to induce regeneration of the damaged skeletal muscle [32] . Furthermore, fibrin possesses specific binding sites for angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor-2 (bFGF-2) and insulin-like growth factor-1 (IGF-1) that improve myogenesis [109] [110] [111] [112] .
Nevertheless, fibrin hydrogels are not without their limitations. One key impediment is that when formed at high concentrations of fibrinogen, a dense microstructure might appear, restraining the cell infiltration, migration and transport of certain soluble factors; whereas low concentrations of fibrin hydrogels result in a soft and loose mechanical network with limited mechanical integrity and stability [113] . A recent study attempted to circumvent some of these limitations concurrently with demonstrating the influence of material porosity on the cellular functions and regenerative capacities. Fibrin hydrogels were incorporated with beads formed by gelation of gelatin and subsequent dissolution to form micrometre-sized pores. Human umbilical cord mesenchymal stem cells (hUCMSCs), which were encapsulated in this macroporous fibrin-microbead constructs, showed improved viability and myogenic differentiation [29] .
Although naturally occurring biological hydrogels are the preferred choice for controlling cell growth, proliferation and differentiation (due to their resemblance to native tissue), they are limited in terms of precisely controlling their properties, processing and biofunctionality. Synthetic hydrogels, unlike their naturally derived counterparts, can be closely tuned in concert with certain requirements of the cell therapy application, particularly the mechanics that most resembles the native cellular microenvironment. Characteristics such as viscoelasticity, modulus, permeability and degradability can be controlled using a strategy that balances between the effective number of cross-links necessary to form a gel and the polymer weight composition. Another advantage over the natural materials is that synthetic hydrogels tend to have a relatively low risk of pathogen transfer and batch-to-batch variability [80, 108] .
One of the commonly used synthetic materials is polyethylene glycol (PEG), which can be readily manipulated with a broad range of chemical and mechanical properties and offers superior biocompatibility, making it particularly attractive from a regulatory standpoint [114, 115] . Gilbert et al. [35] deomsntarted that SCs cultured on soft PEG hydrogel with an equivalent native muscle elasticity of 12 kPa, retained their stemness in comparison with cultures in Petri dishes (approx. 3 GPa). Moreover, when subsequently transplanted into mice, these cells showed better engraftment capability, dynamic proliferation and self-renewal capacity, making this culture strategy useful in skeletal muscle regeneration. Further functionalization of the synthetic hydrogels could be attained by endowing the material with bioactive molecules, peptides, proteins or other biological hydrogels. Such a strategy is thoroughly exemplified by conjugation of PEG hydrogel with the pendant RGD peptide, a motif present in ECM proteins and recognized by integrins for cell adhesion [80] . Simple physiological reaction mechanisms, such as incorporation of PEG hydrogels with maleimide cross-linking reaction chemistry, were also identified as a potential route to achieve more precise control over the conjugation of bioactivity functionalities. For example, maleimide reactive groups enabled highly specific conjugation of RGD and protease-degradable cross-linking peptides with a PEG backbone. Systematic modulation of the compositional properties of this PEG-peptide modular hydrogel revealed that encapsulated C2C12 myoblast viability and differentiation rate in 3D culture were dependent mainly on polymer density and bioadhesive ligands. In this way, the researchers were able to provide key microenvironment cues to guide the formation and self-alignment of multinucleated myotubes which exhibit contraction under external stimuli in vitro [30] .
Other functionalities such as polymeric nanoparticles, silicate nanoplatelets, carbon nanotubes (CNTs), graphene and synthetic clays can be applied to form nanocomposite hydrogels. These nanocomposites can be engineered to control certain environmental stimuli that can be important in tissue engineering applications [116, 117] . For instance, Ramó n-Azcó n et al. [53] showed that by aligning CNTs into gelatin methacryloyl (GelMA) hydrogels through dielectrophoresis, they improved the electrical conductivity of the hydrogel construct for fabricating contractile myotubes. Some promising hybrid hydrogels can also be designed by combining both natural and synthetic materials for functional skeletal muscle regeneration. One such hydrogel is the PEGfibrinogen (PF), a photopolymerizable hydrogel, which enables the controlled and localized gelation when seeded with a cell suspension [118] , both in vitro and also in vivo, particularly within a damaged muscle [65] . This semi-synthetic hydrogel has shown to support skeletal muscle survival, growth and maturation [68] . These materials are capable of supporting cell growth and undergoing proteolytic degradation via their biological domains while still providing robust mechanical properties emanating from their synthetic components [106] .
Alginate hydrogels have also been used for skeletal muscle regeneration. When used without any modification, these hydrogels possess some critical disadvantages such as reduced mechanical properties, uncontrollable degradation and lack of cellular adhesion receptors. These drawbacks can be overcome by adding modifications to the alginate that would assure improved cell attachment and sustained delivery of bioactive molecules. One such example is the oxidized alginate-gelatin (OA-GEL) cross-linked hydrogel that recently has drawn attention as a potential material for rehabilitating various tissues. The material is particularly useful because of its tunable properties, which depend on the OA/GEL weight ratio and oxidation degree (OD) [119] . Moreover, not only is OA considered a better cross-linking agent for gelatin, when compared with alginate, the modification of gelatin with OA appears to compensate poor mechanical stability of gelatin and several known drawbacks of alginate including low cell adhesiveness and proliferation [119 -121] . A recent study which took advantage of the ex vivo differentiation potential of MSCs into skeletal muscle was the first to experimentally evaluate the effect of OA-GEL hydrogel sheets on the proliferation of seeded MSCs isolated from Wharton's jelly of the umbilical cord [36] . The OA-GEL hydrogel sheets were prepared by self-cross-linking of OA and gelatin without employing any extraneous cross-linking agents. Subsequently, when the OA/GEL weight ratio was adjusted to 30/70 and the OD to 30%, these hydrogels exhibited the best combination of mechanical properties, degradation, proliferation response and behaviour of the cultured human WJ-derived UC-MSCs for muscle tissue engineering applications [36, 122] . Alginate-polyacrylamide hydrogels with an interpenetrating polymer network (IPN) structure are another strong candidate for skeletal muscle applications. Tuning both elastic and viscoelastic properties of this hydrogel, mainly by altering the concentrations of monomer and the cross-linker-N,N'-methylene bisacrylamide (MBAA)-was shown to achieve almost the same stress relaxation behaviour and elastic modulus of porcine muscle tissue [37] .
In addition to the hydrogel's constituent, the mechanical properties of a hydrogel also play a major role in the efficacy of the cell therapy for skeletal muscle disorders. In some cases, by modulating the mechanical properties of the hydrogel, key microenvironment cues are provided to direct the development and self-alignment of multinucleated myotubes, which exhibited contraction under external stimuli in vitro [30] . Moreover, the differentiation of MSCs can be controlled by the stiffness of the extracellular environment, particularly when employed on rigid substrates mimicking the stiffness of skeletal muscle. In this case, a myogenic lineage specification is promoted. MSCs have been shown to differentiate into myogenic lineage when cultured on collagen-coated polyacrylamide hydrogel with a tensile modulus of 8 -17 kPa and, interestingly, without the addition of specific bioactive molecules into the hydrogels to induce the cell differentiation [38] . Furthermore, a newly emerging method for delivering MSCs, based on injectable thermoresponsive hydrogels, confirmed the high myogenic differentiation efficiency of MSCs on a rigid substrate of 20 kPa [39] . The thermoresponsive hydrogels also undergo a sol-gel transition at physiological temperatures, making these suitable for injection as a solution and subsequent solidification in vivo.
Hydrogels for in vitro engineering skeletal muscle tissues
Given the general challenge of applying hydrogels for skeletal muscle tissue regeneration of muscle injuries, and more stringent demands of applying hydrogels for MD therapies, researchers have sought to custom design these materials based on specific requirements of muscle repair. Indeed, during the last few decades, there has been a strong effort to develop sophisticated new scaffolds for tissue-engineered skeletal muscle constructs used in reparative therapy, as well as for in vitro pre-clinical drug screening. The use of well-refined biomimetic scaffolds and matrices mimicking skeletal muscle microenvironment, for example when combined with well-studied myogenic stem/progenitor cells, plays a pivotal role when forming an artificial skeletal muscle tissue in vitro [58, 123, 124] . A number of methodological approaches have been proposed to form an elongated fascicle-inspired musclemimetic structure using hydrogels. Current attempts focus on duplicating both the unique organization of the muscle structure delineated with aligned parallel myofibres, and the functionality during constant stretching and contraction.
rsif [41] . The methods currently used for engineering such muscle-mimetic structures in vitro range from scaffold anchoring [41, 125] or micropatterning of biomaterials to apply myotube formation [126 -128] to mechanical or electrical stimulation within bioreactors in two-dimensional or 3D settings [129] [130] [131] [132] [133] [134] [135] [136] .
There are two main guidelines in designing a functional in vitro skeletal muscle tissue construct. First is the scaffold architecture, which should provide a supportive platform for muscle differentiation and myogenesis leading to the formation of aligned, densely packed, well-oriented myofibres. Second is the scaffold functionality which can be imparted by artificial electrical stimuli to promote the transition of myogenic cells to functional myofibres. One of the wellknown methods to engineer muscle tissue in vitro involves culturing differentiating myogenic cells within either collagen-I or fibrin-based hydrogels that are anchored at each end to pinned posts (usually made of Velcrow). In this approach, the two anchor posts act as artificial tendons, generating passive tension between anchored hydrogel ends, promoting the fusion of myoblasts into multinucleated myotubes, and ultimately leading to maturation of myotubes to form bundles of aligned, uniaxial and well-organized myofibres [137, 138] . However, evidence showed that these myofibres failed to contract in response to electrical stimulation in the case of collagen-I hydrogels [40, 42] . On the other hand, regarding fibrin-based hydrogels, a number of studies have established that this material is one of the best choices currently for engineering 3D muscle from mouse muscle cells [43, 61, 62] .
Fibrin hydrogels have been widely employed as an in vitro matrix, stimulating substantial matrix remodelling and ECM synthesis and exhibiting stiffness resembling that of skeletal muscle [42, 139] . This material is therefore a good choice for investigating cellular processes relevant to skeletal muscle tissue formation. One of the earliest fibrin-based engineered skeletal muscle tissue has been reported by Huang et al. [41] ; they fabricated an engineered self-organizing 3D skeletal muscle using fibrin hydrogels. They showed that fibrin hydrogels provide a supportive environment that promotes 3D growth and fusion of primary neonatal rat myogenic cells. Strikingly, these engineered muscle tissues were shown to gain great functional results in generating specific forces of 36 mN mm 22 . Although significantly lower than the 260 mN mm 22 force measured in native muscles, this is still higher than what was achieved with collagen-based muscle constructs upon electrical stimulation [41, 140] . Further improvements, particularly in the static forces that were generated within the constructs during culture, were sought in order to enable rodent skeletal muscle tissues to be engineered with contractile properties comparable with those of native muscle. Several studies worked on obtaining this aim by optimizing both fibrin hydrogel composition and the starting cell population. The composition of the fibrin hydrogel was carefully optimized to potentiate cellmatrix interactions, by including Matrigel, a basement membrane cell extract containing laminin and collagen IV. Subsequently, optimizing the starting cell population was also necessary, to improve cell survival, maturation, myogenic fusion and SC pool maintenance. Furthermore, optimizing transport of nutrient and oxygen was accomplished by providing dynamic culture conditions and decreasing the construct dimensions [43, 44] .
The reproducible fabrication of relatively larger (approx. 2 cm 2 ) engineered skeletal muscle tissue constructs has been demonstrated using a cell/fibrin-based hydrogel micromoulding technology [45, 141] . These engineered muscles comprise highly aligned, cross-striated myofibres, exhibiting native-like niche with quiescent SCs (Pax7þMyoD2). The constructs showed a capacity to generate contractile forces and to regenerate post-toxin-induced in vitro injury [62] . Neal et al. [46] demonstrated the formation of 3D fasciclelike muscle tissues by applying a sacrificial outer moulding technique in which muscle tissues were produced in cylindrical fibrin hydrogels strips suspended between two anchors. Owing to the compaction of the fibrin hydrogels, this approach was able to produce cylindrical tissue structures with tunable diameter, densely populated with highly aligned C2C12 myoblasts along the cylindrical axis figure 3a. Given this sacrificial outer moulding system together with C2C12 myoblasts transduced with a lightgated cation channel, channelrhodopsin 2 (ChR2), the formation of muscle strips capable of optically stimulated contraction was achieved [47, 48] .
To accelerate the production and growth rate of skeletal muscle-like constructs, an innovative bioreactor-based 3D culture system (MagneTissue) was developed. This system is able to govern different mechanical strains applied to the construct in a cyclic, static or ramp manner. Murine myoblasts embedded in a fibrin hydrogel ring scaffold were cultured in the MagneTissue and stimulated throughout the culture duration. The novelty of this bioreactor system lies in the fact that the generated tension is not solely relying on the cell-mediated static strain induced upon the scaffold anchoring and compaction. Instead, this system subjects the engineered muscle constructs to individually adjustable strain regimes and thus is able to mimic more accurately the physiologically relevant strains. In this regard, constructs subjected to static mechanical strain stimulation during 9 days exhibited a greater extent of muscle maturity, highly organized fibrin fibrils with widespread sarcomeric patterning and enlarged diameter in comparison with non-stimulated constructs [49] .
Bearing in mind the anisotropic nature of skeletal muscle tissues-which contain bundles of uniaxially directed and densely packed myofibres-one must consider that inappropriate alignment of myofibres may directly reduce the efficacy of transmission and contraction of artificial muscle fibres [142] . Respectively, some sophisticated approaches hold great promise in developing anisotropic hydrogels that precisely imitate native arrangement of skeletal muscle ECM. These hydrogels can be formed as scaffolds with a unidirectional structure that guide myoblast fusion, gene expression, and ultimately encourage the formation of long, thick and anastomosing myotubes [5, 27, 143] . One application of this strategy was developed by Wang et al. [50] whereby they designed a nanofibre-based, self-supporting scaffold structure that was fabricated from core-shell columns and sheets. The structure was engineered by amalgamating polycaprolactone (PCL)/silk fibroin/polyaniline (PANi) scaffolds to form the aligned nanofibre yarn (NFY) core via a dry-wet electrospinning method and then encapsulating the NFY within a poly(ethylene glycol)-co-poly(glycerol sebacate) (PEGS-M) photocurable hydrogel (shell). Given the high water capacity of the hydrogel shell, it effectively protected both the nanofibres and the cells (C2C12 myoblasts), and facilitated an efficient rate of nutrient exchange that aided myogenic differentiation. This design successfully overcame the limitations for the formation of dense, aligned myotubes, in that two-dimensional matrices are typically unable to meet the requirements of self-supported scaffolds, and there are many difficulties associated with 3D permeable scaffolds in terms of engendering uniform cell seeding figure 3b.
Another interesting application was reported by Kang et al. [51] they employed an integrated tissue-organ printer to fabricate 3D skeletal muscle tissue. This 3D bioprinting system used clinical imaging data to determine the shape rsif.royalsocietypublishing.org J. R. Soc. Interface 15: 20170380 and dimensions of the defect area before a multi-dispensing system was employed to print constructs containing cellladen hydrogels in addition to sacrificial Pluronic F-127 hydrogels and PCL support structures. After 3 days in the growth media, the cells (C2C12 myoblasts) were elongated along the longitudinal axis of the bundles, and after 7 days, muscle-like structures with aligned myotubes were observed. The anisotropic structure was maintained due to the interplay between cell contractility and surrounding matrix mechanics that led to the compaction of the hydrogel so that its bundles remained taut. After 14 days, the myotubes that had developed within these constructs showed well-organized muscle fibre structures that expressed myosin heavy chain, desmin and acetylcholine receptor (AchR) clusters.
Another prevalent strategy to attain a good functionality of muscle tissue in vitro that would resemble the native function, is by applying artificial electrical stimulation. Engineering novel electrically conductive and mechanically robust hydrogels, which can closely regulate the behaviour of electrically active cells, is one promising approach that has made some headway in fabricating advanced functional muscle in vitro. One recent application of this approach involves the fabrication of electrically conductive hydrogels through the inclusion of conductive materials like polymers (poly(3,4-ethylenedioxythiophene) (PEDT) PANI) or CNTs inside a hydrogel [52, 144] . The complexes with this additional constituent exhibited increased electrical conductivity and thus promoted the development of muscle cells which are electroactive cells [145] . Incorporation of CNTs in GelMA hydrogels resulted in hybrid GelMA-CNT hydrogels with improved mechanical properties and electrical conductivity [146] . The CNTs were aligned within GelMA hydrogels to endow them with tunable and anisotropic electrical conductivity, to a higher extent than GelMA hydrogels with randomly oriented CNTs and pure GelMA. Having superior and anisotropic electrical conductivity, GelMA-aligned CNT hydrogels could exploit more efficiently the electrical stimulation that was applied along the direction of the aligned CNTs for the fabrication of muscle tissues in vitro [53] . C2C12 myoblasts grown on GelMA vertically aligned CNT hydrogels yielded a higher amount of functional myofibres than myoblasts cultured on the GelMA hydrogels with randomly or horizontally oriented CNTs [54] . Another example of electrically conductive hydrogel was fabricated by employing palladium-based metallic glass sub-micrometre wires (PdMGSMWs) to enhance the electrical conductivity and mechanical strength of GelMA hydrogels. In comparison with pure GelMA, the hybrid GelMA-PdMGSMW hydrogels showed better performances in regulating adhesion, expansion and differentiation of encapsulated C2C12 myoblasts as well as increased formation, contractility and metabolic activity upon electrical stimulation [55] .
Micropatterning strategies have been established as an effective platform to engineer spatially controlled cell and tissue architecture in vitro and can also be used to orchestrate the adhesiveness of substrates and cells on synthetic surfaces for a long period [56, 147] . The ability of hydrogel-based 3D micropatterned scaffolds to modulate myoblast culture topology and alignment towards tissue formation in a micrometric manner, confers an advantage for engineering well-organized skeletal muscle tissue. Soft polyacrylamide hydrogels with physiological elastic modulus (15 kPa) that were micropatterned in parallel lanes, demonstrated a remarkable formation of human myotubes in vitro (30 mm in width and length ranging from 500 mm to 1 mm), organized in independent parallel bundles [56] . Some thermoresponsive micropatterned hydrogels were proposed as a straightforward tool to fabricate well-defined 3D muscle tissues with anisotropically aligned myotubes. These hydrogels supported the creation of a confluent monolayer of aligned myoblasts. Then, when the temperature was reduced from 378C to 48C, these hydrogels were disassembled and enabled the rapid harvest of cell sheets with a striated structure of ECM and myoblasts, to the desirable substrate through conformal contact with the hydrogel. Finally, the topologic micropatterns promoted the creation of aligned myotube on the harvested cell sheet [57, 148] .
Drug screening
Currently, the most immediate benefit of these bioengineering technologies for treating inherited muscle diseases such as MDs may lie in the forthcoming advancement of human in vitro assays designated for preclinical trials of a candidate drug, cell or therapeutic gene. Many of the in vitro models described in the previous section can potentially serve as screening tools. In fact, some studies have focused explicitly on designing hydrogel scaffolds and cells that mimic the muscle disorder pathophysiology to screen experimental drugs for a particular disease. The identification of specific factors that positively affect muscle function in boys with DMD using such model systems, for example, could potentially lead to novel therapies that improve quality of life [149] . In this context, a decisive advantage of drug screening using engineered tissues is the ability to exploit cells from either a human origin with a muscular disorder or an equivalent rodent model of the disorder, for the in vitro fabrication of a disease skeletal muscle analogue.
Vandenburgh and colleagues [58] developed a 3D miniature bioartificial muscle (mBAMs) for screening purposes. These constructs were initially derived from healthy murine myoblasts cast in either fibrin or collagen hydrogels, attached to two flexible microposts at its ends to evaluate functionality (figure 3c). The same group later pioneered the development of 3D mBAM constructs derived from mdx murine myoblasts, using the same technique [58] , capable of generating active forces that were comparable to control mBAMs (engineered from conditionally immortalized murine myoblasts). The mdx mBAMs were used to evaluate the impact of 31 potential compounds of interest for DMD therapy with a myoforce analysis device. This was used as a high-content drug screening (HCS) technology aimed at distinguishing compounds that modify muscle strength. Among the 31 compounds, 11 significantly increased mdx mBAM tetanic force, when compared with placebo-treated controls. Furthermore, they were able to recognize beneficial compound interactions in addition to the deleterious interactions of combinatorial compounds routinely administered to some DMD patients [59] . The similarity in response of in vitro mdx muscle models and DMD patients to many identical compounds clearly illustrates the potential of this system as a useful preclinical model for appraising and predicting the outcomes of various treatments for DMD and other muscle disorders. Animal muscle constructs made from mdx-derived myoblasts (or other MD animal models) do not fully capture the disease phenotype seen in human patients. Therefore, the fabrication of human in vitro skeletal muscle constructs for drug screening purposes is motivated by the necessity to gain better outcomes in human patients. A previous study has documented the usage of an immortalized human myoblast line from a DMD patient who may serve as a more useful and accurate screening tool for identifying compounds able to improve the attenuation and the progressive muscle weakening associated with the disease [150, 151] .
Miniaturized structures of a DMD model have been developed for studying the pathological mechanisms of the disease at the cellular level [59, 60] . A study conducted by Serena and colleagues [60] reported the in vitro fabrication of human myotubes carrying genetic diseases, based on micropatterned polyacrylamide hydrogels coated with either laminin, fibronectin or matrigel. Human myoblasts derived from biopsies of both healthy and DMD-affected donors were cultured onto micropatterned polyacrylamide hydrogels, and later showed increased alignment, differentiation and sarcomeric striations depending on hydrogel stiffness and the coating protein. An optimal hydrogel modulus of 15 kPa showed the highest percentage of myotubes exhibiting actin-myosin striation, regardless of the protein used for coating. Furthermore, in contrast to dystrophic myotubes cultured on glass, the dystrophic myotubes cultured on polyacrylamide hydrogels were endowed with the ability to recapitulate particular pathological hallmarks, such as the decreased expression of dystrophin in DMD (compared with healthy myotubes) and the unchanged production of sarcomeric units, which is known to be independent from dystrophin expression in the case of DMD [60] .
Tissue-engineered models of human contractile muscle represent a better tool for performing 'clinical trials in a dish' to appraise both safety and efficacy of candidate therapies without human subjects. A large quantity of data have validated the potential application of this tissue-engineered skeletal muscle as a preclinical platform for drug screening. However, the advantages of using human myoblasts are undermined by the facts that 3D in vitro skeletal muscle constructs have yet to exhibit mesureable contraction. Murine myoblast constructs can be used for drug screening because they exhibit high contractility [41, 43, 58, 138] , whereas in vitro 3D skeletal muscle constructs derived from human myoblasts fail to exhibit the same contractility in vitro, relying instead on measurements of passive force [40, 152, 153] .
Madden and co-workers [61] were the first to report a 3D culture model of human skeletal muscle that responds to electrical and biochemical stimulation in a manner similar to native skeletal muscle. This model was developed by culturing human myogenic cells expressing a GCaMP6 genetically encoded calcium indicator, within a supporting matrix composed of fibrin gel and matrigel. The engineered muscle tissues consisted of aligned and striated myofibres which displayed intact calcium handling, functional acetylcholine and b-adrenergic receptors, and exhibited both physiological force -length and force-frequency relationships (figure 3d). When stimulated electrically or chemically, the engineered skeletal muscle responded much like a normal tissue in terms of releasing calcium ions followed by twitching. The average tetanus force generated by the engineered muscles was far lower than that reported for adult muscle, but was similar to the values measured in foetal human muscle [154, 155] . Testing three classes of pharmaceutical drugs revealed that they had similar effects on the engineered muscle as on normal muscle tissue under clinical settings.
These results further validate the potential application of the engineered human skeletal muscle as a preclinical platform for drug testing. Although drug screening models can provide an improved predictive pharmacological assay that can potentially serve as an alternative to costly animal testing, further modifications are still needed in terms of mimicking the physiological mechanical and electrical cues of native skeletal muscle tissue. For example, integration of functional AchR within myobundle is crucial for assessing the effects of neuromuscular junctions.
Transplantation of in vitro fabricated muscle tissues
Concomitant with the drug screening platforms, there is an unmet clinical need for engineered skeletal muscle tissue for transplantation and replacement, partly or entirely, of diseased or damaged skeletal muscle. This can entail complete restoration of the damaged tissue with the engineered construct, or having the construct support for endogenous regeneration. The rationale for using in vitro fabricated muscle tissue was based on the low viability and survival of cells engrafted upon transplantation via bolus injection. This prompted and motivated researchers to develop alternative approaches through which a striated muscle tissue can be pre-engineered in vitro and then implanted, replacing a segment or an entire wasted muscle. When compared with the administration of undifferentiated myogenic cells, whether alone or embedded in a hydrogel scaffold, the implantation of an engineered tissue that mimics the in vivo structure can provide immediate structural repair, prolong the graft survival and facilitate better functional in vivo integration. This approach offers some additional advantages, including for example the in vitro preconditioning of the tissue implants, which enables them to attain maximum survival and specific mechanical and metabolic attributes. Another advantage is the ability to significantly minimize mechanical deterioration by using a tissue structure whose functional capacity is known prior to the implantation. Tissue implants have also the potential to be individually designed according to a patient's muscle architecture-with a so-called personalized medicine approach-thereby assisting in the immediate return to function for the patient. Finally, the native microenvironment for the cells within the pre-fabricated muscle provides better sustainability against adverse immune response upon implantation [27, 40, 104] .
It is accepted, although not unanimously, that one of the key steps in engineering a functional muscle tissue in vitro is to precisely mimic the in vivo muscle milieu by exploiting the most appropriate combination of cells and biomaterials. These two design parameters are chosen based on the characteristics that may largely determine the success or failure of the implant. Once the engineered tissue is implanted, the biomaterial should then exhibit biocompatibility, promote the integration of the transplanted tissue within the host tissue, support additional angiogenesis and facilitate neurogenesis. In addition, it is equally important to establish a connection to tendons [156, 157] . Considering the pathology in some forms of disease such as MD, where damage to muscles is widespread and covers most of the body's musculature, a therapy based on reconstituted skeletal muscle seems more practical for the repair of one select muscle group. The systemic delivery of cells may be preferred, but little headway has been made in investigating systemic delivery-based [25, 65, 158, 159] . Moreover, these patients' quality of life could be exceedingly improved by providing at least a single functional muscle that would allow them to retain an ability to communicate (e.g. a muscle in the finger that helps interface with a computer via keystrokes).
The most challenging issue for the in vitro fabrication of skeletal muscle tissues is the scaling-up to larger constructs needed for most human indications. Although promising, the use of the above strategy may thus be limited to small graft sizes on account of poor supply of oxygen and nutrients to the implanted muscle cells. In this case, the diffusion of oxygen and other nutrients into the deepest layers of the tissue is severly limited. While this does not constitute a restriction for small skeletal muscle constructs used in the drug screening platforms, large constructs designed for human implantation and reaching about 400 mm in diameter result in a necrotic core, limiting the use of this strategy. Larger dimensions of muscle tissue implants may undergo excessive and irreversible hypoxic damage due to the high metabolic demand that leads to abrupt and unmet consumption of diffused oxygen from the host capillaries [41, 138, 160, 161] .
Perhaps, the best way to overcome the transport limitations is to design the engineered construct with prevascularized structures that can facilitate immediate transport upon implantation into the host. Hydrogels will need to be further modified to provide stimulation that enhaces the post-impantation transport in skeletal muscle, particularly for larger muscle implants. Such modifications should enable the hydrogels to effectively support the infiltration of host cells, including fibroblasts, macrophages and endothelial cells, into the graft, while accelerating vascular and neural ingrowth through the release of pro-angiogenic growth factors to promote cell survival and engraftment. Fabricating prevascularized skeletal muscle constructs for accelerated vascular integration in vivo has gained growing recognition as a potential strategy to improve graft survival and stability, and enhance therapeutic effects [31, 73, 160, 161] . A recent study found that vascular networks formed in vitro were capable of supporting and maintaining the survival of constructs cultured with heterogeneous cell populations derived from mouse hind-limb skeletal muscle, for 40 days in culture [162, 163] .
Although this application is still in its infancy, a recent pilot study has demonstrated successfully in vivo implantation of an in vitro bioengineered muscle tissue [62] . The engineered muscle bundles (approx. 1.5-mm diameter, 1.25 cm long) were created in vitro by culturing and differentiating neonatal rat myogenic cells using a cell/fibrin-hydrogel micromoulding approach, whereby the tissue fibres are anchored at each end with tendon-mimetic Velcro tabs pinned inside a polydimethylsiloxane (PDMS) chamber. Along with the structural maturation, these constructs were able to generate contractile force after two to four weeks in culture. Remarkably, these biomimetic muscles elicited contractile-force amplitudes of about 10-100 fold higher than previously described in vitro engineered muscles [43, 162, 164, 165] . The in vivo behaviour of the engineered muscles was monitored using a mouse dorsal window implantation model. The engineered muscle bundles were transplanted into a skinfold window chamber, perpendicular to the panniculus carnosus muscle layer of the dorsal skin in a nude mouse. During two weeks post implantation, a steady ingrowth of blood-perfused microvasculature was observed, and the implanted muscle bundles became increasingly integrated with the host muscle. Moreover, at the same time point following implantation, an increase in the amplitude of calcium transients matched a gradual increase in contractile force of the engineered muscle in such a way as to make it effectively contract as native neonatal skeletal muscle (figure 3e) [62] .
Hydrogels as a delivery vehicle

Delivery of cells
In recent years, a number of studies have shown that in skeletal muscle disorders such as MD, cell transplantation can be of benefit by way of augmenting the innate response to the disorder. Unfortunately, these approaches have shown limited clinical success due to major technical problems including decreased cell viability upon transplantation and limited migration of the transplanted cells in situ, among others [166] [167] [168] [169] [170] [171] . Accordingly, the development of a sophisticated matrix for the delivery of cells would be indispensable in managing the hurdles associated with cell transplantation for skeletal muscle repair. In an ideal case, an engineered biomatrix could help in determining the initial distribution of implanted cells within and around the damaged muscle tissue, improving encapsulated cell retention and promoting integration processes with the host tissues by providing inductive cues for myogenesis, angiogenesis and neurogenesis. Finally, this matrix should degrade in a gradual manner to encourage complete native muscle ingrowth [31, 172] .
Micro-encapsulation of transplanted cells in a semipermeable hydrogel is an increasingly popular and refined strategy, which aims to tackle the latter obstacles, serving as a guide or inductive template to facilitate endogenous skeletal muscle repair. Hydrogels are appealing biomaterials for encapsulating cells for delivery to damaged muscle tissues and may prove to be efficient in cases that require sustained wound healing such as in the degradative process of dystrophic tissue, which requires a longer repair time. Implementation of in situ delivery of cells and/or bioactive molecules within hydrogel vehicles can be done by either surgical implantation or injection. Injectable hydrogels have remarkable merit as therapeutic matrices, as they can be applied in a minimally invasive manner at the target site. This feature renders them particularly relevant to clinical use, avoiding unnecessary and highly invasive surgeries, thereby reducing the extent of damage incurred upon administration and delivery in the target tissue. The in situ gelation of the injectable hydrogels is often triggered by temperature, pH, UV light or ionic strength environment [173] . Given their viscoelastic properties and in situ gelation, these hydrogels are ideal for therapeutic application in muscle injury, providing structural support to the damaged muscle through effective moulding to adapt accurately to the defect shape and space filling of voids caused by defects. Apart from their structural support, they also enable high levels of biomolecule and metabolite diffusion into the implant milieu and are capable of forming a local niche that would develop into functional tissue [174, 175] .
Injectable hydrogels derived from decellularized skeletal muscle ECM that possesses a composition closely matched to the native tissue have been reported to increase arteriole and capillary density, even without the addition of external cells. Therefore, these materials can be injected to improve neovascularization in the skeletal muscles [63] . Rossi et al. [64] were one of the first to show the application of a hydrogel technology for the functional recovery of damaged skeletal muscle in vivo. They designed a controlled delivery system for either SCs or MPCs via an injectable photopolymerizable hyaluronan-based hydrogel. The transplantation of either SCs or MPCs embedded within the hyaluronanbased hydrogels into ablated tibialis anterior (TA) of mice was shown to improve the ability of myogenic precursor cells to restore muscle tissue after ablation. The formation of new myofibres led to functional recovery as measured by muscle contraction strength. However, the effects were more pronounced with SCs being delivered in the hydrogel, compared to the hydrogel alone or the hydrogel with MPCs. Besides, the hydrogel-SC complex supported the development of a neural and vascular lattice. This combination of both effects in repairing the damaged skeletal muscle niche is considered to have a fundamental role in functional muscle reconstruction.
More recently, Fuoco and co-workers [65] used PF hydrogels with tunable mechanical properties to make injectable cell carriers to guide and promote the therapeutic effect of donor MABs, perivascular myogenic progenitor cells. MABs have been widely investigated in preclinical studies, showing a positive effect on muscle fibre regeneration, and in alleviating the dystrophic phenotype in dystrophin-deficient mice upon intra-arterial delivery [65, 92, 97, 176] . Their study disclosed the feasibility of delivering MABs within injectable PF hydrogels, as a locally administered cell therapy for repairing dystrophic muscles at an advanced stage of the disease. PF-embedded MAB grafts were injected directly intramuscularly into the TA muscle of old dystrophic a-sarcoglycan knockout (a-SGKO)/SCID-beige mice model, which are known to exhibit a more severe MD behaviour compared to other common strains such as the mdx mouse. The PF hydrogel was shown to provide protection from host inflammation, preventing cell apoptosis and improving MAB survival and engraftment in the in vivo model. The protection was afforded by the hydrogel characteristics, including its density and biodegradability. The results indicated an enhanced therapeutic effect of the donor MABs as a result of the PF carrier. Laminin staining highlighted better organization of regenerated muscle fibres in the TA treated with the PF-MABs compared with PBS-MABs. Furthermore, the higher number of nlacZþ/Pax7þ cells observed in TA muscles injected with the PF-MABs (compared with the PBS MABs) indicated that the PFencapsulated MABs replenish the muscle SC pool figure 4a [65] . Although Fuoco et al. [65] and Rossi et al. [64] employed different cell types and hydrogels, the two studies reached the same conclusions, mainly the importance of using hydrogels in applications to promote the muscle recovery of damaged and dystrophic muscles.
It is noteworthy that the early functional impairments associated with MD are characterized by an accelerated agerelated decline in skeletal muscle regeneration. In this regard, several common underlying mechanisms have been found, such as depletion of the SC pool and reduced activity, accompanied by loss of self-renewal capacity and deviant Notch signalling, as well as reduced myogenic potential [177] [178] [179] . During the past several years, the concept of transplanting SCs in an attempt to enhance therapeutic muscle repair in aged and diseased muscles such as in MDs has gained growing recognition as a potential therapeutic strategy. Yet, the success of the method has so far been limited due to poor cell survival as well as limited proliferation and migration [180] . Recent results have converged to highlight the explicit influence of aberrant p38a/b mitogen-activated protein kinase (MAPK) signalling in aged SCs on the diminished ability of these cells to undergo self-renewal. Identifying this overactive signalling pathway as a potential Another study by Fuoco et al. [67] described a novel approach in which PF hydrogel scaffolds were used to rejuvenate aged skeletal MPs. The hydrogels were used to replicate the stiffness and mechanical properties as well as the 3D structure of young muscle ECM. Following the seeding of aged MP (boar origin) onto the PF scaffolds, their impaired myogenic and angiogenic capacity were significantly recuperated in vitro. For in vivo experiments, aged MP-PF constructs that were implanted subcutaneously into the back of immunocompromised mice resulted in vascularization within the muscle that was almost indistinguishable from that formed with the use of younger cells ( piglet origin). This study demonstrated the ability of PF hydrogel scaffolds to provide a progenitor cell niche that was conducive to supporting myogenic differentiation and angiogenic potentials in vitro and in vivo. The results further support the use of adult MPs as myogenic cells for stem cell-mediated muscle regeneration.
The same group later reported on the in vivo myogenic cell differentiation of human MABs, engineered to express pro-angiogenic placental growth factor (PlGF), encapsulated within PF hydrogels. This study emphasized promising results in recreating a vascularized and innervated skeletal muscle in vivo, using PF hydrogels alone without in vitro preconditioning of the constructs. Once the PF-embedded MABs (expressing PlGF) were grafted in an ablated murine TA injury, a full restoration of the TA muscle defect was observed, generating vascular and neural ingrowth into the engineered muscle grafts. The encapsulated MABs that did not express PlGF showed diminished muscle size and density as well as limited vascular infiltration, suggesting that the survival of muscle fibres was due to the proangiogenic effects of PlGF. These results underscore the potential of replacing damaged muscles with the patient's own cells embedded in a suitable hydrogel carrier, implanted on top of a residual muscle. This strategy would rely on the continuity between the damaged region and the implant, whereby the new muscle is expected to be maintained and transferred with nascent nerves and vessels. This work presents the proof-ofconcept for the formation and regeneration of artificial skeletal muscle tissue in vivo, exhibiting similar physiological properties to a normal TA muscle. However, there is still a long way ahead for reaching human-sized tissues, which will require substantial scale-up [68] .
Thermoresponsive hydrogels have also been used to develop enviornmentally responsive material platforms for cell delivery. Thermoresponsive chitosan/b-glycerolphosphate/collagen (C/GP/Co) injectable hydrogels have been employed to retain both viability and plasticity of the skeletal muscle cells in vivo. SCs were encapsulated into these hydrogels and subcutaneously injected into the dorsum of nude mice. Four weeks after injection, the encapsulated SCs maintained their viability and stemness, and extensive ingrowth of blood vessels was also observed [76] . Among the widely investigated hydrogels for biomedical applications, fibrin hydrogels have been most commonly used as delivery vehicles for cell therapy in skeletal muscle. An early in vivo study demonstrated the use of fibrin for the delivery of donor primary myoblasts into a rat skeletal muscle; the results showed that the fibrin leads to the integration of donor cells with the host muscle tissue in a localized and time-dependent manner [69] . Fibrin microthreads cultured with human muscle cells and delivered into damaged muscles of immunecompromised mice induced skeletal muscle regeneration [32] . Growing muscle cells around blood vessels was reported by Borschel et al. [70] whereby myoblast cultures of adult rat soleus muscle were suspended in a fibrin hydrogel placed within tubular silicone chambers. The chambers were situated around the femoral vessels in vivo. Upon explanting at three weeks, the chambers were filled with a new muscle tissue construct comprising cylindrical flaps, with clear femoral vessels crossing their lengths. The resulting 3D muscle tissue, when explanted after three weeks, produced longitudinal contractile force ex vivo when electrically stimulated.
Delivery of bioactive molecules
A variety of bioactive molecules, including cytokines and growth factors, have the potential to ameliorate the muscle healing process, due to their ability to govern the skeletal muscle regeneration. Nevertheless, one major limiting factor for their pharmaceutical use is their short half-life in vivo due to the host immune response and enzymatic processes. To enhance the bioavailability and the half-life of bioactive molecules as therapeutic agents, researchers have started taking advantage of the encapsulating capabilities of hydrogels to design a delivery system with varied affinities to different bioactive molecules. This notion has become especially relevant in the field of cell therapy, where the identification and utilization of factors that potentiate resident or exogenous MPCs to form de novo muscle fibres are the focus of intense research. A wide range of cytokines, growth factors and other bioactive molecules have been found to be essential for supporting the viability and differentiation of stem cells alongside the skeletal myogenic lineage. The most effective bioactive molecules in this context are myogenic growth factor IGF-1 and angiogenic growth factor VEGF; they both have been reported to positively influence muscle cell populations in vitro and in vivo [71, 72, 123, 135] .
Premised on the concepts of controlled growth factor delivery fom hydrogels, one group used a hydrogel delivery system to achieve sustained release of IGF-1 in vivo. A PEGfibrin (PEG-Fib) hydrogel was conjugated with IGF-1 and injected into the lateral gastrocnemius muscle of the tourniquet-injured (TK) limb of a rat. Histological analysis showed that the PEG-Fib-IGF therapy resulted in a marked improvement of muscle function and structure compared with the saline control, suggesting that PEG-Fib-IGFmediated therapy induces myogenic differentiation and accelerates the recovery of the skeletal muscle [71, 72] . A similar approach, which concurs with the beneficial effects attributed to exogenously delivered bioactive molecules, was previously reported by Borselli et al. [73] to promote myogenesis, angiogenesis and innervation. Injection of alginate hydrogels loaded with incorporated IGF-1 and VEGF not only enhanced the myoblast survival but also resulted in improved functional muscle regeneration demonstrated by myoblast recruitment for neomuscle formation following ischaemic muscle injury. These results emphasize the importance of vascularization and innervation for regenerating muscles using this strategy, particularly on the ability to promote cell survival upon implantation and to facilitate better integration with the surrounding muscles. In this regard, stimulation of angiogenesis may elevate the myogenic stem cell pool which is available to promote muscle regeneration. Consequently, sustained levels of VEGF using hydrogel delivery vehicles results in a greater degree of angiogenesis than in bolus VEGF delivery.
Although the studies reviewed in this section have been conducted on the ischaemia/reperfusion injury model, their results validate the state-of-the-art application of molecularly designed hydrogels, presenting different biophysical cues and endowed with capabilities for releasing a multitude of bioactive and chemotactic signals in injured skeletal muscle tissues. It is important to note that DMD is characterized by abnormal blood flow after muscle contraction (also known as functional ischaemia). In these terms, dystrophin deficiency causes loss of neuronal nitric oxide synthase (nNOS) from the sarcolemma and reduces paracrine signalling of musclederived nitric oxide (NO) to the muscle microvasculature. As a result, the diseased muscle fibres become susceptible to functional muscle ischaemia during exercise [181] [182] [183] . Recent data obtained in preclinical studies in the mdx mouse have shown considerably advantages to restoring NO signalling in dystrophic mouse muscle. This indicates that diminishing muscle ischaemia may enable DMD/BMD patients to engage in more activities with less muscle injury and fatigue, thereby elevating quality of life and delaying disease progression [184] . Further study of how hydrogel-based delivery systems of bioactive factors-including NO signalling molecules-can be used as guides to promote endogenous regeneration of injured skeletal muscle tissues is required. Nevertheless, given their particular properties, hydrogels are a promising biomaterial source for this purpose.
Delivery of cells and bioactive molecules
One of the obstacles in implementing cells, even when encapsulated, is their reduced viability post implantation. As a result, a large number of myogenic cells are needed for any type of muscle cell therapy to overcome poor survival. Such a large number of cells might be difficult to attain from standard muscle biopsy or surgical samples. For this purpose, for example, the sustained release of myogenic IGF-1 can be beneficial to intensify implanted myoblast survival and even assist in muscle repair [73] . A proof-of-concept study demonstrated the potential of gingival mesenchymal stem cells (GMSCs) to be used in the regeneration of muscular tissues when encapsulated in injectable and biodegradable 3D RGD-coupled alginate hydrogel microspheres loaded with a cocktail of myogenic growth factors. This designed delivery vehicle was loaded with myogenic growth factors containing Forskolin (FSK), a cell differentiation inducer; 6-Bromo-1-methylindirubin-3 0 -oxime (MeBIO), a component that plays a role in the regeneration and proliferation of mammalian cardiomyocytes; and bFGF, which is a crucial element for the survival and differentiation of MSCs in muscle regeneration.
The in vitro findings clearly indicated that GMSCs encapsulated in alginate hydrogel with an intermediate modulus of elasticity (10-16 kPa) exhibited the highest capacity for myogenic differentiation compared with softer (less than 5 kPa) or stiffer (greater than 20 kPa) hydrogels. More interestingly, the expression level of myogenic-related genes (MyoG, MyoD and Myf5) in GMSCs encapsulated in alginate hydrogel was higher than in GMSCs that were not encapsulated. Most importantly, during in vivo trails, the formation of small islands of muscle-like structures was observed eight weeks following subcutaneous transplantation of GMSCs in microspheres into immunocompromised mice figure 4b [74] .
Liu et al. [75] emphasized the benefits of alginate hydrogel microbeads as a delivery vehicle for cytokines and other bioactive molecules, such as FGF-1, VEGF and platelet-derived growth factor (PDGF). Owing to their ability to undergo cross-linking under physiological conditions, these hydrogels are able to retain the bioactivity of these growth factors. The alginate hydrogels were further modified to demonstrate a slow, low-level consistent release of the encapsulated growth factors, by coating them with a semi-permeable membrane of poly-Lornithine (PLO) to get alginate-PLO-alginate (APA) microbeads. They showed that culturing human urine-derived stem cells (USCs) on APA microbead hydrogels encapsulating a cocktail of growth factors was possible. Furthermore, subcutaneous engraftment of these constructs into nude mice promoted myogenic differentiation of the USCs, as well as increased angiogenesis and innervation of the grafted constructs.
A recent study by Hwang and co-workers [77] demonstrated the synergistic effect of the co-application of human adipose-derived stem cells (h-ADSCs) and bFGF, incorporated into a gelatin-poly(ethylene glycol)-tyramine (GPT) hydrogel, on promoting muscle regeneration. They tested this system with a lacerated gastrocnemius muscle of mice, showing that this treatment was able to eliminate the development of fibrosis within the tissue. Although ADSCs alone did show some degree of improvement to the muscle, their association to the loaded hydrogel and bioactive cues showed dramatically enhanced contractile force of the healing tissue muscles, decreased localized fibrosis and increased multinucleated regenerating myofibres, as well as vascular structures in the targeted area.
Wang and co-workers [78, 79] developed a biodegradable, temperature-responsive, partially cross-linked, alginate hydrogel scaffold with a shape-memory effect as per body temperatures. These hydrogels were designed to deliver IGF-1, VEGF and primary myoblasts to injured muscle tissue. When tested in vitro, 90% of recombinant IGF-1 that was embedded in these hydrogels was released over several days enabling the survival, proliferation and migration of skeletal muscle cells within the scaffold over a 28-day period [78] . A subsequent in vivo study by the same group showed that this scaffold degraded progressively as it delivered its biological payload over a six-week period, a time frame comparable to the kinetics of new muscle tissue formation. These results confirmed that the material degradation process promoted the proliferation of primary myoblasts [78, 79] .
Future challenges
Future research in hydrogel development for muscle injuries and MD must consider a number of issues that will help to rsif.royalsocietypublishing.org J. R. Soc. Interface 15: 20170380 improve upon the current state of the art. For example, the mode of hydrogel implantation must be optimized for treating both large and small muscles. A localized injection of hydrogel may not be feasible when treating large muscle groups; inter-arterial delivery of the hydrogel may be a more realistic approach for such indications. There are few examples where intra-arterial injections can be facilitated with in situ cross-linking; but pre-formed hydrogel microcapsules could provide a much better and more straightforward solution for inter-arterial injections. In addition, in situ crosslinking and gelation of the hydrogel may not be suitable for every mode of delivery. For hydrogel cross-linking involving photochemistry, for example, the penetration of light into deep muscle groups will become an obstacle to successful gelation of the implant. Cross-linking methods using a two-part solution may be more suitable in such cases.
Integration of the hydrogel implant within the host tissue must be optimized with respect to both the cellular payload and the host response. Ideally, the hydrogel should provide temporary support for cell implantation, protecting the cells from inflammatory assaults, without overly restricting cell mobility or impeding the restructuring of new muscle regeneration in the implant locale. Hydrogels that degrade too slowly or confine their encapsulated cellular payload may render the cellular integration too restrictive to facilitate repair in a timely fashion. Conversely, hydrogels that degrade too quickly or permit rapid infiltration of the host inflammatory cells may not provide sufficient protection for the cellular payload from the initial inflammatory assault in the harsh environment of the muscle injury or dystrophic muscle. Optimization of hydrogel properties, including mesh size, mechanical properties and biodegradation properties is crucial in the design process. This will safeguard the embedded cells as they integrate fully with the host tissue.
Hydrogels should also be able to respond to both local and systemic stimuli. Resident muscle SCs, for example, are more likely to differentiate and mature into muscle fibres under mechanical stimulation associated with the native tissue deformations. Mechanical properties of the hydrogels should be closely resembling those of the native tissue so that resident cells may experience appropriate mechanical stimulation. Hydrogels should also be permissive enough to facilitate the transport of nutrients, growth factors, hormones and waste products. For micrometre-scale implants, such as hydrogel microcapsules, these can take advantage of the vascularized network in the native tissue environment to ensure proper supply. Alternatively, for larger hydrogel implants with bulk properties that do not enable sufficient supply to resident cells, active transport can be facilitated by expediting angiogenesis within the implant. For this purpose, numerous studies have been focused on using hydrogels with angiogenic growth factors and vascular cells to ensure that proper transport as an integral part of the implant.
The development of new hydrogels, and the refinement of existing hydrogels, should be based on the knowledge of biology together with materials engineering. Such combinatorial designs will bring engineered hydrogel implants to the next level in this expanding research field. For example, bulk hydrogel implants must combine angiogenic factors, MPCs, permissive transport properties, appropriately matched modulus and in situ gelation chemistry to ensure the appropriate mechanical, structural and bioactive features for successful integration and eventual muscle regeneration. For dystrophic muscles, the design of the implant is even more critical because of the harsh environment and unique biological milieu that is associated with the disease. Only through better design concepts in biomaterial development will this field be able to overcome many of the most difficult obstacles that are currently preventing the successful transplantation and functional integration of MPCs to dystrophic muscles. As the field makes progress with more sophisticated cell delivery hydrogel vehicles for this purpose, the true realization of cell therapy in muscle repair and MD can become a reality.
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